((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
(Correction of a typo in the name of the CDC agency in paragraph 1)
AstraZeneca’s antibody therapy
AZN.L and Sanofi SASY.PA were 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), according to a study by the US Centers for Disease Control and Prevention (CDC).